United States securities and exchange commission logo





                          November 15, 2022

       David Southwell
       President and Chief Executive Officer
       TScan Therapeutics, Inc.
       830 Winter Street
       Waltham, Massachusetts 02451

                                                        Re: TScan Therapeutics,
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed November 9,
2022
                                                            File No. 333-268261

       Dear David Southwell:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Tyler
Howes at 202-551-3370 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              William D. Collins,
Esq.